Changes in peripheral blood level of regulatory T cells in patients with malignant melanoma during treatment with dendritic cell vaccination and low-dose IL-2
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-03-01 / Scand. J. Immunol. 2011 Mar;73(3):222-33Exosome-loaded dendritic cells elicit tumor-specific CD8+ cytotoxic T cells in patients with glioma
/in Dendritic Cells, Exosome, Glioblastoma, International Publications /von 2011-02-19 / J. Neurooncol. 2011 Sep;104(3):659-67Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2011-02-10 / Gene Ther. 2011 Jun;18(6):584-93IL-15 and type I interferon are required for activation of tumoricidal NK cells by virus-infected dendritic cells
/in Dendritic Cells, International Publications, Newcastle Disease Virus /von 2011-02-09 / Cancer Res. 2011 Apr;71(7):2497-506Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells
/in Dendritic Cells, Hyperthermia, International Publications /von 2011-02-03 / Clin. Cancer Res. 2011 Apr;17(8):2474-83Recent developments in cancer vaccines
/in Dendritic Cells, International Publications /von 2011-02-01 / J. Immunol. 2011 Feb;186(3):1325-31[Roles of Newcastle disease virus in human acute monocytic leukemia in vitro and in vivo]
/in Acute Leukemia, International Publications, Newcastle Disease Virus /von 2011-02-01 / Zhongguo Dang Dai Er Ke Za Zhi 2011 Feb;13(2):149-52Dendritic cell vaccination against ovarian cancer–tipping the Treg/TH17 balance to therapeutic advantage?
/in Dendritic Cells, International Publications, Ovarian Cancer /von 2011-01-28 / Expert Opin Biol Ther 2011 Apr;11(4):441-5Oncolytic virus-initiated protective immunity against prostate cancer
/in International Publications, Newcastle Disease Virus, Prostate Cancer /von 2011-01-18 / Mol. Ther. 2011 Apr;19(4):797-804IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de